Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Xeris Biopharma Holdings develops and commercializes therapies for chronic endocrine and neurological diseases. Its core products include Recorlev for Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. The company leverages proprietary formulation technologies (XeriSol and XeriJect) to create stable, ready-to-use injectable drugs and partners with other biopharmaceutical firms to expand its pipeline and delivery options.
This description was generated via AI from an annual report. Updated about 1 year ago.